NOTCH-induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells by Zhao, Di et al.
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
5 4 5 3jci.org   Volume 124   Number 12   December 2014
Introduction
Aldehyde dehydrogenases (ALDHs) are family members of 
NAD-dependent enzymes that catalyze the oxidation of alde-
hydes to acids. To date, 19 ALDH members have been identified 
in the human genome. They are localized in the cytoplasm, mito-
chondria, or nucleus and have been implicated in a wide variety of 
biological processes, including the detoxification of exogenously 
and endogenously generated aldehydes and the metabolism of 
vitamin A, alcohol, and ROS. In the ALDH1 family, ALDH1A1 
(also known as retinaldehyde dehydrogenase 1, RALHD1) mainly 
catalyzes the conversion of retinaldehyde to retinoic acid (RA) 
in vitamin A metabolism (1). RA enters the nucleus and binds to 
and activates the RA receptors (RARs) or the retinoid X receptors 
(RXRs), which are nuclear transcription factors that promote tar-
get gene expression (2). The genes downstream of RA are involved 
in many important biological processes, including cell differentia-
tion, proliferation, and lipid metabolism.
Ziouzenkova et al. found that Aldh1a1–/– mice suppressed adi-
pogenesis and reduced adipocyte size in vivo, thereby conferring 
resistance to high-fat diet–induced obesity (3). It was also reported 
that ALDH1A1 regulates a thermogenic program in white adipose 
tissue (4). Recently, abundant evidence has shown that ALDH1A1 
activity is a marker for stem cells — primarily hematopoietic stem 
cells (HSCs) and cancer stem cells (CSCs) — in both normal and 
malignant tissues (5–7). In 1990, it was first reported that HSCs 
are highly enriched for ALDH1, while less primitive cells express 
lower levels of this protein (8). Later, other groups developed a 
convenient method to measure intracellular ALDH1 activity in 
live cells (7, 9). To date, this method is widely used to isolate HSCs 
from blood and CSCs from many tumor types, including leukemia 
(5, 8, 9), breast cancer (6), melanoma (10), lung cancer (11), and 
others (12, 13). Ginestier et al. found that ALDH1 is a good marker 
for malignant human mammary stem cells and that high–ALDH1 
activity cell populations leads to substantial tumorigenesis, poor 
prognosis, and increased metastasis in xenografted mouse mod-
els (6). Furthermore, ALDH1A1 expression in breast cancer was 
found to correlate with advanced disease stage, triple negativity, 
and poor outcome following neoadjuvant chemotherapy (14).
CSCs are believed to contribute to tumor metastasis and poor 
prognosis and are defined by 2 key characteristics: the tumorigenic 
potential to give rise to new tumors and the capacity for self-re-
newal and differentiation. The balance between self-renewal and 
differentiation regulates tumor growth and metastasis. The devel-
opment of specific therapies targeting CSCs offers great potential 
to improve the survival of cancer patients, especially those with 
metastatic disease (15, 16).
NOTCH signaling plays an important role in development 
by modulating cell-fate determination, cell survival, and pro-
liferation (17). The NOTCH receptors, including 4 members in 
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expressed (Supplemental Figure 1C) and endogenous ALDH1A1 
(Figure 1E and Supplemental Figure 1D). Using this antibody, we 
also detected K353 acetylation of endogenous ALDH1A1 in human 
liver tissue, and this signal was completely blocked by preincuba-
tion with the antigen peptide (Figure 1F). Collectively, these stud-
ies demonstrate that ALDH1A1 is acetylated at K353 in vivo.
To determine the effect of ALDH1A1 acetylation on its activ-
ity, we measured ALDH1A1 enzyme activity in the oxidation 
of retinaldehyde. Inhibition of deacetylases with NAM treat-
ment decreased ALDH1A1 enzyme activity by 50% (Figure 1G). 
Moreover, ALDH1A1K353R and ALDH1A1K353Q mutants displayed 
only 40% and 50%, respectively, of WT activity levels (Supple-
mental Figure 1E), and treatment with NAM had little effect on 
the activity of either mutant (Figure 1H). These data suggest 
that K353 acetylation inhibits ALDH1A1 activity. To definitively 
demonstrate the effect of K353 acetylation on ALDH1A1 activity, 
we used the system of genetically encoding Nε-acetyllysine to 
prepare recombinant proteins in E. coli (28, 29). This expression 
system produced ALDH1A1 proteins with 100% acetylation at 
K353 due to the suppression of the K353-UAG stop codon by the 
Nε-acetyllysine–conjugated amber suppressor tRNA. We prepared 
both unacetylated and K353-acetylated ALDH1A1 and compared 
their enzymatic activity. As shown in Figure 1I, K353-acetylated 
ALDH1A1 abolished catalytic activity. Collectively, these results 
demonstrate that acetylation at Lys-353 inhibits ALDH1A1 activ-
ity. However, we have no evidence to support the notion that 
acetylation participates in the regulation of ALDH1A1 protein sta-
bility (Supplemental Figure 1F).
SIRT2 activates ALDH1A1 by deacetylating Lys-353. Treat-
ment with the SIRT inhibitor NAM, but not the HDAC inhibi-
tor TSA, increased ALDH1A1 acetylation at K353 (Figure 1A), 
indicating that a member of the SIRT family of deacetylases is 
involved in K353 deacetylation. Because ALDH1A1 is a cyto-
plasmic protein, we coexpressed ALDH1A1 with the 2 cytosolic 
SIRT deacetylases SIRT1 and SIRT2. We found that SIRT2, but 
not SIRT1, decreased ALDH1A1 acetylation at Lys-353 (Figure 
2A and Supplemental Figure 2A) and increased its activity by 
52% (Figure 2A). Furthermore, coexpression of WT SIRT2, but 
not the inactive H187Y mutant, reduced ALDH1A1 acetylation 
and increased its enzyme activity (Figure 2B), supporting the 
idea that SIRT2 deacetylase activity is important in regulating 
ALDH1A1 K353 acetylation and enzyme activity. Consistent 
with this observation, knocking down SIRT2 increased K353 
acetylation of ectopically expressed ALDH1A1 and significantly 
(P = 0.0006) decreased its activity by 31% (Figure 2C).
We then ectopically expressed WT and H187Y-mutant SIRT2 in 
HEPG2 cells and found that only WT SIRT2 downregulated endoge-
nous ALDH1A1 acetylation at Lys-353 (Figure 2D). Conversely, 
SIRT2 knockdown elevated ALDH1A1 acetylation (Figure 2E), and 
treatment with the SIRT2 inhibitor AGK2 increased K353 acetylation 
as well (Supplemental Figure 2B). Next, we examined the physical 
interaction between SIRT2 and ALDH1A1 and found that ectopically 
expressed SIRT2 was coprecipitated by ALDH1A1 (Figure 2F). More-
over, endogenous SIRT2 could also be coimmunoprecipitated by 
the ALDH1A1 antibody in HEPG2 cells (Figure 2G). Together, these 
observations demonstrate a specific and prominent role of SIRT2 in 
the K353 deacetylation and enzymatic activation of ALDH1A1.
mammals (NOTCH1–4), are activated by binding with a number 
of ligands (delta-like 1, 3, and 4; jagged 1 and 2). Upon ligand 
binding, the intracellular NOTCH domain is cleaved and translo-
cates to the nucleus, where it regulates downstream target gene 
transcription (18). The NOTCH link to cancer was first reported in 
human T cell leukemia, in which aberrant NOTCH signaling pro-
motes tumorigenesis (19–21). Later, numerous studies established 
that the NOTCH1 signaling pathway plays a role in breast cancer 
development (22). Recently, many reports have suggested a func-
tion of the NOTCH signaling pathway in promoting self-renewal 
of mammary stem cells and breast cancer stem cells (23–26). 
Harrison et al. reported that pharmacologic or genetic inhibition 
of NOTCH reduced stem cell activity in vitro and tumor formation 
in vivo. The NOTCH pathway is an appealing therapeutic target in 
CSC research, and several investigational NOTCH inhibitors are 
being developed. Here, we report that NOTCH signaling activates 
ALDH1A1 by inducing deacetylation, thereby promoting breast 
CSC self-renewal and tumor growth.
Results
Lys-353 acetylation decreases ALDH1A1 enzyme activity. Given 
the critical role of ALDH1A1 in stem cells, we sought to investi-
gate its regulation. Recent studies have revealed a broad role of 
lysine acetylation in metabolic enzyme regulation. We examined 
previous acetylation proteomic datasets and found that 10 puta-
tive acetylation sites were identified in ALDH1A1 by mass spec-
trometry (ref. 27 and Supplemental Table 1; supplemental material 
available online with this article; doi:10.1172/JCI76611DS1). To 
confirm lysine acetylation in ALDH1A1, we ectopically expressed 
FLAG-tagged ALDH1A1 in HEK293T cells and then treated the 
cells with trichostatin A (TSA), an inhibitor of histone deacety-
lases (HDACs) I and II and nicotinamide (NAM), an inhibitor of 
the sirtuin (SIRT) family of deacetylases. Western blotting with 
anti–pan-acetyllysine antibody showed that the acetylation of 
ALDH1A1 was elevated approximately 2.3-fold after treatment 
with NAM, but not TSA (Figure 1A). This result suggests that ecto-
pically expressed ALDH1A1 is acetylated in cells and is deacety-
lated by a member of the SIRT family of deacetylases.
We then mutated each of 10 putative acetylation sites individ-
ually to arginine (R) or glutamine (Q) and examined their acety-
lation. Only K353R and K353Q mutations resulted in a significant 
reduction (80% and 78%, respectively) in ALDH1A1 acetylation 
(Figure 1B), indicating that K353, which is evolutionarily con-
served from D. melanogaster to mammals (Supplemental Figure 
1A), is a major acetylation site in ALDH1A1. Mutations of the other 
9 putative acetylation sites had little effect on ALDH1A1 acetyla-
tion (Supplemental Figure 1B).
To further confirm Lys-353 acetylation of endogenous 
ALDH1A1, we generated an antibody specifically recognizing 
K353-acetylated ALDH1A1 by immunizing rabbits with K353- 
acetylated peptide. The specificity of the anti-AcALDH1A1(K353) 
antibody was verified, as it recognized the K353-acetylated pep-
tide but not the unacetylated control peptide (Figure 1C). Western 
blotting with this antibody detected ectopically expressed WT, but 
only weakly detected K353R-mutant ALDH1A1 (Figure 1D). More-
over, we found that treatment of cells with the deacetylase inhib-
itor NAM strongly increased K353 acetylation of both ectopically 
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ALDH1A1 in HEPG2 cells after either ectopic expression or knock-
down of PCAF. We found that PCAF ectopic expression increased 
K353 acetylation of endogenous ALDH1A1 (Figure 3D), while 
PCAF knockdown reduced ALDH1A1 acetylation (Figure 3E). Fur-
thermore, both ectopically expressed and endogenous ALDH1A1 
and PCAF displayed physical interaction, as determined by co-IP 
experiments (Figure 3, F and G). Together, these results indicate 
that PCAF regulates ALDH1A1 enzyme activity by acetylating K353.
Acetylation of ALDH1A1 inhibits ALDH1+ cell populations and 
CSC self-renewal in breast cancer. Ginestier et al. found that high 
ALDH1 activity (labeled as the ALDH1+ cell population) is a 
good marker of breast CSCs (6). Considering the effect of K353 
PCAF acetylates ALDH1A1 at Lys-353 and decreases its enzyme 
activity. To identify the acetyltransferase responsible for ALDH1A1 
acetylation at K353, we examined 12 lysine acetyltransferases 
(KATs) and found that only PCAF (p300/CBP-associated factor, 
also known as KAT2B) regulated ALDH1A1 acetylation at K353 
(Figure 3A and Supplemental Figure 3), whereas the other acet-
yltransferases had little effect (Supplemental Figure 3). Notably, 
coexpressed PCAF also decreased ALDH1A1 activity by 50% (Fig-
ure 3B), while knocking down PCAF reduced K353 acetylation and 
enhanced ALDH1A1 activity (Figure 3C).
To determine whether PCAF could affect endogenous 
ALDH1A1 acetylation, we analyzed K353 acetylation of endogenous 
Figure 1. Acetylation at Lys-353 decreases ALDH1A1 enzyme activity. (A) ALDH1A1 was acetylated, and FLAG-ALDH1A1 was transfected into 293T cells, 
followed by treatment with the deacetylase inhibitor TSA or NAM. ALDH1A1 acetylation was analyzed by Western blotting with pan–anti-acetyllysine 
antibody (α-Ac). (B) K353 mutation decreased ALDH1A1 acetylation. (C) Specificity of the antibody against K353-acetylated ALDH1A1 was determined. 
The nitrocellulose membrane was spotted with different amounts of acetylated K353 peptide or unmodified peptide, as indicated, and probed with 
anti-AcALDH1A1(K353) antibody (α-K353Ac). (D) The anti-AcALDH1A1(K353) antibody recognized WT but not K353R-mutant ALDH1A1. (E) Treatment 
with NAM increased endogenous ALDH1A1 acetylation at K353. HEPG2 cells were treated with NAM. Endogenous ALDH1A1 protein levels and K353 
acetylation were determined. (F) Endogenous ALDH1A1 was acetylated at Lys-353. K353 acetylation of endogenous ALDH1A1 in human liver tissues was 
determined using the anti-AcALDH1A1(K353) antibody preincubated with or without acetylated K353 peptide. (G and H) Inhibition of SIRT family deacet-
ylases reduced the enzyme activity of WT, but not K353R/Q-mutant, ALDH1A1. FLAG-tagged WT or mutant ALDH1A1 protein was expressed in 293T 
cells, and transfected cells were treated with or without NAM and then purified by IP using an anti-FLAG antibody. Enzymatic activity was measured and 
normalized to protein levels. (I) Acetylation at K353 inhibited ALDH1A1 enzyme activity. Recombinant WT and K353-acetylated ALDH1A1 protein were 
prepared by genetically encoding Nε-acetyllysine in E. coli. UnAc-ALDH1A1, unacetylated ALDH1A1. (G–I) Enzymatic activity was measured and normal-
ized to protein levels. Relative enzyme activity data represent the mean ± SD of triplicate experiments.
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was reduced by 81% when compared with that in the ALDH1– cell 
population. We observed a similar effect in the breast cancer cell 
line MCF-7 (Supplemental Figure 4).
These data suggest that decreased K353 acetylation, along 
with increased expression of ALDH1A1, contribute to increased 
ALDH activity in the ALDH1+ cell population. Interestingly, we 
also detected decreased PCAF expression and increased SIRT2 
expression in the ALDH1+ cell population (Figure 4C and Sup-
plemental Figure 4), which may contribute to decreased K353 
acetylation of ALDH1A1.
In order to confirm the decrease in K353-acetylated 
ALDH1A1 in breast CSCs, we repeated these experiments 
using several breast cancer tissue samples. Primary breast 
cancer cells were cultured, and stem cells were separated by 
ALDEFLUOR assay. The results showed that the ALDH1+ cell 
population, which has self-renewal properties, accounted for 
about 3.5% of cells in one of the breast cancer tissues (Figure 4, 
acetylation on ALDH1A1 activity, we investigated the functions of 
ALDH1A1 acetylation in regulating CSC self-renewal. We identi-
fied ALDH1+ cell populations in the breast cancer cell line MDA-
MB-468 using aldehyde dehydrogenase–dependent fluorophore 
(ALDEFLUOR) assay and found that about 15% of cells showed 
high ALDH1 activity (Figure 4A), which is close to what has pre-
viously been reported (30). Then, we sorted the ALDH1+ cell 
populations (10%) and ALDH1– cell populations (10%) according 
to fluorescence intensity and determined their mammosphere-
forming ability, which is a commonly used assay for self-renewal. 
We found that the ALDH1+ cell population showed much stron-
ger mammosphere-forming activity, consistent with the enrich-
ment of CSCs in this cell population (P = 0.0002, Figure 4B). 
Compared with the ALDH1– cell population, the ALDH1+ cell 
population showed higher ALDH1A1 protein expression levels, 
but decreased K353 acetylation (Figure 4C). The relative level of 
K353-acetylated ALDH1A1 versus total ALDH1A1 in ALDH1+ cells 
Figure 2. SIRT2 deacetylates and activates ALDH1A1. (A) SIRT2, not SIRT1, decreased K353 acetylation and increased ALDH1A1 activity. 293T cells were 
transfected with the indicated plasmids. FLAG-ALDH1A1 was immunoprecipitated, and ALDH1A1 activity was assayed. (B) SIRT2 deacetylase activity was 
required to increase ALDH1A1 activity. 293T cells were cotransfected with FLAG-ALDH1A1 and SIRT2 WT or the inactive mutant H187Y. (C) SIRT2 knockdown 
increased K353 acetylation and decreased ALDH1A1 activity. 293T cells were transfected with the indicated plasmids and SIRT2 siRNA oligonucleotides. 
ALDH1A1 was immunoprecipitated and activity was assayed. ALDH1A1 acetylation at K353 was determined by Western blotting. (A–C) ALDH1A1 activity 
was normalized to protein levels, and relative enzyme activity data represent the mean ± SD of triplicate experiments. (D) SIRT2 overexpression decreased 
endogenous ALDH1A1 K353 acetylation. Plasmid expressing SIRT2 WT or the inactive mutant H187Y was transfected into HEPG2 cells, and endogenous K353 
acetylation and ALDH1A1 were determined. (E) SIRT2 knockdown increased endogenous ALDH1A1 K353 acetylation. siRNA oligonucleotide targeting SIRT2 
was transfected into HEPG2 cells, and the levels of endogenous K353 acetylation, ALDH1A1, and SIRT2 protein were determined by Western blotting. (F and 
G) ALDH1A1 bound to SIRT2. (F) The indicated plasmids were cotransfected into 293T cells, and ALDH1A1-SIRT2 binding was determined by IP and Western 
blotting. (G) Interaction of endogenous ALDH1A1 and SIRT2 in HEPG2 cells was determined by IP and Western blotting.
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Collectively, these results demonstrate that K353 acetylation of 
ALDH1A1 could inhibit self-renewal of breast CSCs by reducing 
ALDH1A1 activity.
Considering the roles of SIRT2 in regulating ALDH1A1 
K353 acetylation and that SIRT2 protein levels were increased 
in ALDH1+ cell populations, we investigated whether SIRT2 
regulates breast CSCs. Our data showed that treatment with 
the SIRT2 inhibitor AGK2 decreased ALDH1+ cell populations 
in primary breast cancer cells, and this effect depended on the 
treatment duration and concentration of AGK2 (Figure 5E and 
Supplemental Figure 5). Collectively, our data show that K353 
acetylation of ALDH1A1 regulates ALDH1+ cell populations and 
CSC self-renewal in breast cancer.
NOTCH activates ALDH1A1 by inducing deacetylation to pro-
mote breast CSCs. The NOTCH signaling pathway is known to reg-
ulate self-renewal of breast CSCs (23–26). This led us to determine 
whether K353 acetylation of ALDH1A1 is modulated by NOTCH 
signaling. FLAG-ALDH1A1 was transfected into 293T cells, and 
the transfected cells were treated with the NOTCH inhibitor DAPT 
D and E). Importantly, we found that SIRT2 protein levels were 
substantially increased in ALDH1+ cells isolated from primary 
tumors when compared with the levels in ALDH1– cells (Figure 
4F). Associated with this increase in SIRT2, the relative level of 
K353-acetylated ALDH1A1 versus total ALDH1A1 was reduced 
by 77%. Our results demonstrate a strong correlation between 
reduced ALDH1A1 acetylation and breast CSCs.
To determine the function of ALDH1A1 and its acetyla-
tion in breast CSCs, ALDH1A1 was knocked down in MDA-
MB-468 cells. We found that ALDH1A1 knockdown reduced the 
ALDH1+ cell population and mammosphere-forming activity 
by more than 80% and 90%, respectively (Figure 5, A and B), 
indicating that ALDH1A1 plays an important role in CSC self- 
renewal. We then stably reintroduced WT or K353R/Q mutants 
into ALDH1A1-knockdown cells and determined the mammo-
sphere-forming activity of these cells. Cells that expressed the 
K353Q or K353R mutants showed reduced ALDH1+ cell popula-
tions and decreased mammosphere-forming activity compared 
with those that reexpressed WT ALDH1A1 (Figure 5, C and D). 
Figure 3. PCAF acetylates ALDH1A1 at Lys-353 and decreases its enzymatic activity. (A and B) PCAF overexpression increased ALDH1A1 acetylation at 
K353 and decreased ALDH1A1 activity. 293T cells were transfected with the indicated plasmids, and FLAG-ALDH1A1 was immunoprecipitated for activity 
and acetylation analysis. (C) Knockdown PCAF decreased K353 acetylation and increased ALDH1A1 activity. 293T cells were transfected with the indicated 
plasmids and PCAF siRNA oligonucleotides. ALDH1A1 was immunoprecipitated and its activity was assayed. ALDH1A1 acetylation at K353 was determined 
by Western blotting. (A–C) ALDH1A1 activity was normalized to protein levels, and relative enzyme activity data represent the mean ± SD of triplicate
experiments. (D and E) PCAF increased endogenous ALDH1A1 K353 acetylation. Plasmid expressing PCAF was transfected into HEPG2 cells (D), or siRNA 
oligonucleotide targeting PCAF was transfected into HEPG2 cells (E). Endogenous K353 acetylation, ALDH1A1, and PCAF protein levels were determined 
by Western blotting. (F and G) ALDH1A1 bound with PCAF. (F) HEK293T cells were transfected with the indicated plasmids. ALDH1A1-PCAF binding was 
determined by IP and Western analysis. (G) Endogenous ALDH1A1-PCAF interaction in HEPG2 cells was determined by IP and Western blotting.
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(a γ-secretase inhibitor that blocks activation of the NOTCH intra-
cellular domain). As shown in Figure 6A, inhibition of NOTCH 
signaling increased K353 acetylation and reduced the enzymatic 
activity of ALDH1A1. DAPT treatment also reduced SIRT2 pro-
tein levels, but had no effect on PCAF. Furthermore, when the 
NOTCH pathway was activated by DLL4 (the extracellular lig-
and of NOTCH), ALDH1A1 K353 acetylation was reduced, while 
SIRT2 protein levels were increased (Figure 6B). Concomitant with 
the reduced K353 acetylation, ALDH1A1 activity was increased. 
These data suggest that NOTCH signaling can activate ALDH1A1 
by decreasing K353 acetylation. To confirm NOTCH signaling 
in the regulation of ALDH1A1, we cotransfected 293T cells with 
ALDH1A1 and NOTCH1 intracellular domain (NICD1), which is an 
activate component of the NOTCH pathway. We found that coex-
pressed NICD1 induced deacetylation and activation of ectopically 
expressed ALDH1A1 (Figure 6C).
We then investigated the effect of the NOTCH pathway on 
endogenous ALDH1A1 acetylation. MDA-MB-468 cells, MCF-7 
cells, and primary human breast cancer cells were treated with 
DAPT or DLL4 for the indicated durations in Figure 6, D and E). 
Inhibition of the NOTCH pathway reduced SIRT2 protein lev-
els and increased ALDH1A1 K353 acetylation in breast cancer 
cells (Figure 6D and Supplemental Figure 6A). Activation of the 
NOTCH pathway by DLL4 elevated SIRT2 levels and decreased 
ALDH1A1 K353 acetylation (Figure 6E and Supplemental Fig-
ure 6B). Furthermore, when NICD1 was transfected into MDA-
MB-468 cells, SIRT2 protein levels were increased along with 
concomitant ALDH1A1 deacetylation (Supplemental Figure 6C). 
In addition, we determined the SIRT2 mRNA levels and found 
that they were upregulated by NOTCH signaling (Supplemental 
Figure 6D). To gain mechanistic insights, we performed ChIP 
on endogenous NOTCH signaling transcription factors (HES1, 
HEY1, and HEY2) and investigated whether they bound to the 
SIRT2 promoter. However, the ChIP-PCR experiments did not 
detect significant binding of HES1, HEY1, or HEY2 to the SIRT2 
promoter (Supplemental Figure 6E), indicating that NOTCH sig-
naling may regulate SIRT2 expression indirectly. Together, the 
above data suggest a model in which NOTCH signaling activates 
ALDH1A1 via deacetylation by inducing SIRT2 expression.
To address the function of the NOTCH pathway in breast 
CSC populations and self-renewal properties, we treated MDA-
MB-468 cells with DAPT or DLL4 and then determined the 
presence of ALDH1+ cell populations and mammosphere forma-
tion. The results showed that inhibiting the NOTCH pathway 
with DAPT reduced both ALDH1+ cell populations and stem cell 
self-renewal (Figure 7, A and B), whereas, activating the NOTCH 
Figure 4. K353 acetylation of ALDH1A1 decreases in ALDH1+ breast cancer cells. (A) ALDEFLUOR FACS analysis of the breast cancer cell line MDA-MB-468. 
Cells incubated with ALDEFLUOR substrate and the ALDH-specific inhibitor DEAB were used to establish baseline fluorescence (ALDH1–) and to define 
the ALDH1+ region (ALDH1+) (left panel). Incubation of MDA-MB-468 cells with ALDEFLUOR substrate in the absence of DEAB induced a fluorescence shift 
defining the ALDH1+ cell population (right panel). (B and C) ALDH1+ cell populations (top 10% of cells with high fluorescence) and ALDH1– cell populations 
(bottom 10% of cells with low fluorescence) were sorted from MDA-MB-468 cells. Sorted ALDH1+ and ALDH1– cells were measured for mammosphere 
formation (B) and K353 acetylation of ALDH1A1 (K353Ac) (C). Relative K353 acetylation indicates the intensity ratio of K353Ac/ALDH1A1 protein levels. (D) 
Representative FACS analysis of primary breast cancer cells by ALDEFLUOR assay. (E and F) ALDH1+ cell populations (top 3% of cells with high fluores-
cence) and ALDH1– cell populations (bottom 10% of cells with low fluorescence) were sorted from primary breast cancer cells, followed by a mammo-
sphere-forming assay (E) and Western blotting with the indicated antibodies (F). (B and E) Data represent the mean ± SD of triplicate experiments for the 
number of mammospheres per 10,000 transplanted cells.
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pathway with DLL4 increased ALDH1+ cell populations and pro-
moted stem cell self-renewal (Figure 7, C and D). To investigate 
the effect of the NOTCH pathway on ALDH1+ cell populations 
in vivo, we performed xenografting using MDA-MB-468 cells in 
mammary fat pads of NOD/SCID mice. DAPT was intratumor-
ally injected at a concentration of 20 mg/kg/mouse every week. 
Six weeks later, all tumors were collected and digested into a sin-
gle-cell suspension, followed by the determination of ALDH1+ 
cell populations and K353 acetylation. The results indicate that 
inhibition of the NOTCH pathway with DAPT treatment not only 
reduced ALDH1+ cell populations, but also increased K353 acety-
lation in vivo (Figure 7E). These data are consistent with previous 
reports of a positive role for NOTCH in breast CSCs (25). Notably, 
compared with MDA-MB-468 cells reexpressing WT ALDH1A1, 
cells reexpressing K353R or K353Q mutants showed a blunted 
response to DAPT and DLL4 treatment in mammosphere- 
forming assays (Figure 7F), further supporting the notion that 
NOTCH signaling promotes breast CSCs, at least in part by regu-
lating K353 acetylation of ALDH1A1.
ALDH1A1 Lys-353 acetylation inhibits breast cancer tumorigen-
esis and tumor growth. CSCs possess tumorigenic potential and 
contribute to relapse and metastasis. Self-renewal, the most 
important property of CSCs, regulates tumor growth and metas-
tasis. We determined the effect of ALDH1A1 K353 acetylation on 
cell proliferation and tumorigenesis. To this end, endogenous 
ALDH1A1 in MDA-MB-468 breast cancer cells was knocked down 
by shRNA, followed by reintroduction of the shRNA-resistant WT 
ALDH1A1 and K353Q mutant (Figure 5, A and C). 
Notably, cells expressing the ALDH1A1K353Q mutant 
showed reduced cell proliferation (Figure 8A), indi-
cating that ALDH1A1 K353 acetylation inhibits breast 
cancer cell proliferation.
To address the significance of K353 acetyla-
tion in tumorigenesis, we injected varying numbers 
(from 40 cells to 5 × 105 cells) of the MDA-MB-468 
cells expressing WT and K353Q-mutant ALDH1A1 
into mouse mammary fat pads and monitored 
tumor formation. After 3 weeks, the acetylation 
mimetic K353Q-mutant–expressing MDA-MB-468 
cells displayed weaker tumorigenic potential than did the WT 
ALDH1A1–expressing cells (Table 1) and lower tumor-initiating 
cell (TIC) frequencies (Figure 8B). These results support a role 
for ALDH1A1 acetylation in CSCs.
We also evaluated tumor growth in the mouse injected with 
different quantities of MDA-MB-468 cells and found that the 
tumors that developed from cells expressing K353Q-mutant 
ALDH1A1 grew at a significantly (P < 0.001 when measured 4, 
6, and 7 weeks after the initial injection and P = 0.05 when mea-
sured at 5 weeks, respectively) slower rate than did the tumors 
that developed from cells expressing WT ALDH1A1 (Figure 8C). 
Then, the mice were sacrificed, the tumors were collected and 
weighed, and we found that regardless of the number of cells ini-
tially injected, there was a reduction in both the size (Table 2) and 
weight (Supplemental Figure 7A and Supplemental Table 2) of the 
tumors that developed from K353Q-expressing cells compared 
with those that developed from WT ALDH1A1–expressing cells. 
Reintroduced ALDH1A1 expression levels were similar between 
the WT and K353Q-mutant ALDH1A1 cells (Supplemental Figure 
7B). Taken together, our data demonstrate that K353 acetylation 
of ALDH1A1 inhibits self-renewal of breast CSCs, thereby sup-
pressing breast cancer tumorigenesis and tumor growth.
Discussion
High ALDH1 activity is a property commonly associated with 
CSCs. Breast cancer is the first solid tumor in which CSCs were 
defined (31). Besides the CD44+CD24–/lo markers, ALDH1+ was 
also identified as a key marker for breast CSCs. Although the 
precise mechanism of ALDH1A1 in CSC maintenance is not fully 
understood, it likely involves the metabolism of chemicals that are 
involved in stem cell maintenance and/or differentiation. High 
ALDH1A1 activity in stem cells could be maintained by increased 
protein expression and/or posttranslational activation. However, 
posttranslational regulation of ALDH1A1 in CSCs has not been 
investigated. In this report, we identified a novel mechanism of 
ALDH1A1 regulation at the posttranslational level. Our data show 
that ALDH1A1 protein is modified by lysine acetylation, and its 
enzyme activity is inhibited by Lys 353 acetylation. Moreover, 
we identified PCAF and SIRT2 as the enzymes responsible for 
ALDH1A1 acetylation and deacetylation, respectively (Figure 8D). 
This report establishes lysine acetylation as an in vivo biochemical 
mechanism in the regulation of ALDH1A1 activity.
In the breast cancer cells, we found that the cell population with 
high mammosphere-forming potential showed higher ALDH activ-
ity than did the cell population with low mammosphere-forming 
Table 1. MDA-MB-468 cells expressing ALDH1A1K353Q show reduced 
tumorigenic potential
Tumor number/injected mouse number
Cells injected KD + ALDH1A1WT KD + ALDH1A1K353Q
5 × 105 9/9 9/9
5 × 104 9/9 9/9
5 × 103 8/9 4/9
1 × 103 10/12 2/12
200 5/12 0/12
40 0/5 0/5
Xenografting into mammary fat pads was performed using different 
concentrations (5 × 105, 5 × 104, 5 × 103, 1 × 103, 200, and 40 cells per 
mouse) of ALDH1A1-knockdown MDA-MB-468 cells that expressed either  
ALDH1A1WT or ALDH1A1K353Q. Tumorigenesis was determined after 3 weeks. 
KD, knockdown.
Table 2. ALDH1A1K353Q is defective in supporting tumor growth in vivo
Tumor size (mm)
Cells injected KD + ALDH1A1WT KD + ALDH1A1K353Q P value
5 × 105 3.995 ± 0.459 3.520 ± 0.509 0.037
5 × 104 3.777 ± 0.169 3.000 ± 0.276 <0.001
5 × 103 4.077 ± 0.864 2.835 ± 0.274 <0.001
The size of tumors from the mouse injected with 5 × 105, 5 × 104, and 5 × 103 cells was 
monitored every week after tumor formation. Tumor size data from week 7 are shown.  
P values were calculated by Student’s t test. 
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depend on the dominant 
SIRT2 substrates involved in 
the specific cellular process. 
It is possible that the deacet-
ylation of some substrates 
is growth promoting, while 
deacetylation of other sub-
strates is growth inhibitory. 
Therefore, whether SIRT2 
acts as a tumor suppressor or 
an oncogene may be cell con-
text dependent.
A wide range of hor-
mones and morphogens, 
such as NOTCH, WNT, and 
sonic hedgehog, have been 
implicated in stem cell main-
tenance and differentiation. 
The function of NOTCH sig-
naling in stem cells has been 
demonstrated in several cell 
types, including hematopoi-
etic, neural, and mammary 
stem cells. Harrison et al. 
reported that the NOTCH 
signaling pathway promotes 
self-renewal of mammary 
stem cells and breast CSCs 
(25). Interestingly, our study 
reveals that NOTCH signaling 
can regulate ALDH1A1 acet-
ylation. Mechanistically, this 
appeared to be mediated by 
NOTCH signaling–induced 
SIRT2 expression. Inhibition of 
NOTCH signaling decreased 
SIRT2 levels and concomi-
tantly increased ALDH1A1 
Lys-353 acetylation. Likewise, NOTCH activation induced expres-
sion of SIRT2, which could then deacetylate and activate ALDH1A1 
(Figure 8D). NOTCH promoted CSC self-renewal through tran-
scriptional regulation of downstream target genes participating in 
cell-fate determination, cell survival, and proliferation. Our data 
suggest that NOTCH signaling promotes breast CSCs, at least 
in part by activating ALDH1A1 through the indirect induction of 
SIRT2. Further studies are needed to clarify whether the regulation 
of ALDH1A1 acetylation is unique to NOTCH signaling or broadly 
involved in other signaling pathways in stem cell regulation.
Methods
Cell culture and transfection. HEK293T cells were cultured in 
DMEM (Invitrogen) supplemented with 10% newborn calf serum 
(HyClone), 100 units/ml penicillin, and 100 μg/ml streptomycin 
(Invitrogen). HEPG2, MCF-7, and MDA-MB-468 cells were cultured 
in DMEM (Invitrogen) with 10% FCS (HyClone), 100 units/ml pen-
icillin, and 100 μg/ml streptomycin (Invitrogen). All cell lines were 
purchased from the Cell Bank of the Chinese Academy of Sciences 
potential. Furthermore, our findings indicate that ALDH1A1 iso-
lated from the ALDH1+ stem cells had reduced Lys-353 acetyla-
tion. We made similar observations in primary breast CSCs, which 
also displayed low ALDH1A1 Lys-353 acetylation. Therefore, 
lysine acetylation appears to play an important role in the regu-
lation of ALDH1A1 activity and thereby modulates breast CSCs. 
Moreover, cells expressing the acetylated Lys-353 mimetic mutant 
ALDH1A1 displayed lower cell-proliferative and tumor-initiating 
potential, consistent with the reduced tumor growth we observed 
in the mouse xenograft experiments.
In our study, activation of ALDH1A1 by SIRT2-mediated 
deacetylation showed tumor-promoting effects. However, Kim et 
al. reported that SIRT2-deficient mice develop mammary tumors 
(32), suggesting that SIRT2 has tumor-suppressive function. A 
large number of studies have shown that 1 gene can function as 
either a tumor suppressor or an oncogene in a cell context–depen-
dent manner; e.g., SHP2 and PAR3 can be either tumor suppres-
sors or oncogenes (33–37). SIRT2 is known to have many physio-
logical substrates. The effect of SIRT2 on cellular function would 
Figure 5. Acetylation of ALDH1A1 at Lys-353 inhibits ALDH1+ cell populations and CSC self-renewal. (A and B) 
ALDH1A1 plays important roles in regulating ALDH1+ cell populations and maintaining stem cell properties in breast 
cancer cells. ALDH1A1 was stably knocked down in MDA-MB-468 cells, and knockdown efficiency was determined 
by Western blotting (A). ALDEFLUOR (A) and mammosphere-forming (B) assays were performed. (C and D) 
ALDH1A1K353R and ALDH1A1K353Q mutants were defective in supporting ALDH1+ cell populations and the mammo-
sphere-forming activity of MDA-MB-468. The FLAG-tagged shRNA-resistant WT ALDH1A1 or K353R/Q mutant was 
reintroduced into MDA-MB-468 cells, stably knocking down ALDH1A1. Protein levels of reexpressed ALDH1A1 were 
determined by Western blotting (C). ALDH1+ cell populations (C) and mammosphere formation (D) were measured. 
(E) Inhibiting SIRT2 decreased ALDH1+ cell populations. Primary breast cancer cells were treated with AGK2, a SIRT2 
inhibitor, for the indicated concentrations and times. Data represent the mean ± SD of triplicate experiments for 
relative ALDH1+ cell populations and number of mammosphere per 10,000 transplanted cells.
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lysis buffer. Proteins were blotted following standard protocol. Anti-
bodies specific to FLAG (F7425; Sigma-Aldrich), HA (sc-7392; Santa 
Cruz Biotechnology Inc.), ALDH1A1 (12035; Cell Signaling Technol-
ogy), Myc (Shanghai Genomics), PCAF (Epitomics), NICD1 (ab8925; 
Abcam), SIRT2 (NBP1-76879; Novus Biologicals), HES1 (11988S; Cell 
Signaling Technology), HEY1 (ab154077; Abcam), HEY2 (sc-28747; 
Santa Cruz Biotechnology Inc.), and β-actin (A00702; GenScript) 
were purchased. Polyclonal antibodies against pan–anti-acetyllysine 
(antigen: chemically modified acetylated chicken OVA) were gener-
ated by immunizing rabbits at Shanghai Genomics. To generate the 
acetyllysine 353–specific polyclonal antibody against ALDH1A1, syn-
thetic peptide DKEQYDK(Ac)ILDLIES was coupled to KLH as an 
(CAS). Cell transfection was performed using Lipofectamine 2000 
(Invitrogen) or calcium phosphate methods.
Primary breast cancer cell cultures. Fresh breast cancer tissues were 
cut into pieces and digested by collagenase for 2 hours. Cells were 
washed 3 times and collected by centrifugation and then cultured in 
DMEM (Invitrogen) with 10% FCS (HyClone), 100 units/ml penicil-
lin, and 100 μg/ml streptomycin (Invitrogen).
Cell lysis, immunological procedures, and antibodies. Cells were lysed 
in an NP40 buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 
0.3% Nonidet P-40, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 μg/ml pep-
statin, and 1 mM PMSF. Cell lysate (1 ml) was incubated with anti-FLAG 
M2-agarose for 3 hours at 4°C, then the beads were washed 3 times with 
Figure 6. NOTCH activates ALDH1A1 by inducing deacetylation. (A–C) NOTCH signaling promoted SIRT2 expression, decreased K353 acetylation, and 
activated ALDH1A1. FLAG-tagged ALDH1A1 was expressed in 293T cells, followed by treatment with (A) DAPT (an inhibitor of NOTCH) and (B) DLL4 
(extracellular ligand for activating the NOTCH pathway) for 24 hours, or (C) 293T cells were cotransfected with FLAG-ALDH1A1 and FLAG-NICD1 (NOTCH1 
intracellular domain, activated NOTCH1) plasmids. ALDH1A1 was purified by IP, followed by enzyme assay and Western blotting with the indicated anti-
bodies. (A–C) Enzymatic activity was measured and normalized to protein levels, and relative enzyme activity data represent the mean ± SD of triplicate 
experiments. (D and E) The NOTCH signaling pathway increased SIRT2 and decreased endogenous ALDH1A1 K353 acetylation of breast cancer cells.  
MDA-MB-468 cells or primary breast cancer cells were treated with DAPT or DLL4 for the indicated durations. Endogenous NICD1, PCAF, SIRT2, and 
ALDH1A1 protein levels and K353 acetylation were determined by Western blotting.
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The amber construct was overexpressed in Luria-Bertani (LB) cul-
ture medium with spectinomycin (50 μg/ml), kanamycin (50 μg/ml), 
and ampicillin (150 μg/ml), in addition to 2 mM N-acetyllysine 
(Sigma-Aldrich) and 20 mM nicotinamide at the time of induction. 
Both unacetylated and K353-acetylated ALDH1A1 proteins were puri-
fied for enzyme activity analysis.
RNA interference. SIRT2 or PCAF knockdown was car-
ried out using synthetic siRNA oligonucleotides (SIRT2 target 
sequences: ATGACAACCTAGAGAAGTA; PCAF target sequences: 
GCAATTCCCTCAACCAGAAACCAAA) synthesized by Genep-
harma Inc. Cell transfections were performed using Lipofectamine 
2000 (Invitrogen).
ALDEFLUOR assay and separation of ALDH1+ cell populations 
by FACS. The ALDEFLUOR kit (STEMCELL Technologies) was 
used to isolate cell populations with high ALDH1 enzymatic activ-
ity in breast cancer cells. Briefly, 2 × 106/ml cells were suspended 
in ALDEFLUOR assay buffer containing BODIPY-aminoacetalde-
hyde and incubated at 37°C for 40 minutes. For each sample, cell 
aliquots were incubated with or without 50 mM diethylaminoben-
zaldehyde (DEAB), an ALDH-specific inhibitor. ALDEFLUOR stain-
antigen to immunize rabbits (Shanghai Genomics). Antiserum was 
collected after 4 doses of immunization and characterized by Western 
blotting under various conditions, such as peptide competition.
ALDH1A1 enzyme assay. FLAG-ALDH1A1 was ectopically 
expressed, immunoprecipitated, and eluted using 250 μg/ml FLAG 
peptide. The eluent was added to a reaction buffer containing 
10 mM sodium pyrophosphate (pH 7.5), 1 mM NAD+, and 100 μM 
all-trans-retinaldehyde. The change in absorbance (340 nm) result-
ing from NADH production was measured using a Hitachi F-4600 
fluorescence spectrophotometer.
Genetically encoding Nε-acetyllysine in recombinant proteins. To 
generate a homogenously K353-acetylated ALDH1A1 construct, we 
used a 3-plasmid system as previously described (38). This system 
allows for the site-specific incorporation of N-acetyllysine by way of 
a Methanosarcina barkeri acetyl-lysyl-tRNAsynthetase/tRNACUA 
pair that recognizes the amber codon. We cloned WT ALDH1A1 into 
pTEV-8 (pET-21b backboned with the TEV cleavage site), producing a 
C-terminal His6-tagged construct, and incorporated an amber codon 
at Lys-353 (AAA to TAG by site-directed mutagenesis). Bacteria were 
cultured to an OD600 of 0.6 and then induced with 0.5 mM IPTG. 
Figure 7. Mutation of the K353 acetylation site in ALDH1A1 inhibits NOTCH signaling to promote breast CSCs. (A and B) Inhibition of NOTCH signaling 
reduced ALDH1+ cell populations and mammosphere formation. MDA-MB-468 cells were treated with 20 μM DAPT, followed by ALDEFLUOR assay (A) 
and mammosphere-forming assay (B). (C and D) Activation of the NOTCH signaling pathway promoted breast CSCs. MDA-MB-468 cells were treated 
with 10 nM DLL4, followed by ALDEFLUOR assay (C) and mammosphere-forming assay (D). (E) NOTCH inhibitor treatment enhanced K353 acetylation 
and decreased ALDH1+ cell populations in vivo. Xenografting into mammary fat pads was performed using 104 MDA-MB-468 cells, and xenograft tumors 
were treated with DAPT (20 mg/kg/mouse) every week. After 6 weeks, ALDH1A1, K353 acetylation, and ALDH1+ cell populations in tumors were analyzed. 
(F) K353R/Q mutation blocked the effect of the NOTCH signaling pathway on mammosphere formation. MDA-MB-468 cells reexpressing ALDH1A1WT, 
ALDH1A1K353R, and ALDH1A1K353Q mutants were treated with DAPT or DLL4 at the indicated concentrations, and mammosphere formation was measured. 
Data represent the mean ± SD of triplicate experiments for relative ALDH1+ cell populations and number of mammospheres per 10,000 transplanted cells.
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Mammospheres were imaged 
and counted under phase-
contrast microscopy for 3 gen-
erations. Only the mammo-
spheres exceeding 50 μm in 
diameter were counted.
Knocking down and put-
ting back. An shRNA retrovirus 
targeting human ALDH1A1 
was constructed using the fol-
lowing sequences: ALDH1A1, 
5 ′ - C C G G G G A C A AT G C T-
G T T G A A T T T G C C T C -
G A G G C A A AT T C A A C A G -
C A T T G T C C T T T T T G - 3 ′ . 
A control shRNA retrovi-
rus was constructed using 
the following sequences: 
5 ′ - C C G G G A G G C T T C T -
T A T A A G T G T T T A C T C -
G A G T A A A C A C T T A T A A -
G A A G C C T C T T T T T G - 3 ′ . 
Retroviruses were produced 
using a 3-plasmid packaging 
system. Briefly, the pMKO.1-
puro vector expressing the 
shRNA sequence was cotrans-
fected into 293T cells together 
with vectors expressing the 
gag and vsvg genes. Retroviral 
supernatant was harvested 
36 hours after initial plasmid 
transfection and mixed with 
polybrene (8 μg/ml) to increase 
the infection efficiency. For 
transduction, MDA-MB-468 
cells were infected with 5 
ml retrovirus and 5 ml fresh 
medium for 48 hours and then 
selected in puromycin (2 μg/ml) 
for 1 week.
To reintroduce ALDH1A1, FLAG-tagged human ALDH1A1WT, 
ALDH1A1K353R, and ALDH1A1K353Q containing 3 silent nucleotide 
substitutions in the sequence corresponding to the shRNA-targeted 
region were cloned into the retroviral vector (pQCXIH) and were 
cotransfected into 293T cells together with vectors expressing the 
gag and vsvg genes. Retroviral supernatant was used to infect the 
ALDH1A1-knockdown MDA-MB-468 cells. The infected cells were 
selected with hygromycin (2 μg/ml) for 2 weeks.
ChIP. To determine the interaction between the NOTCH path-
way transcriptional factors (HES1, HEY1, and HEY2) and the SIRT2 
promoter, a ChIP assay was performed as previously described (39). 
MCF-7 cells were treated with formaldehyde and lysed using sonica-
tion. Endogenous HES1, HEY1, and HEY2 in cell lysate were immuno-
precipitated with the specific antibody overnight at 4°C. After washing 
several times, DNAs coprecipitated with these transcriptional factors 
were eluted, and the cross-link was reversed before being used as a 
ing was detected using the FITC channel of FACS. The sorting gates 
were established using background fluorescence levels of the DEAB 
control sample. For MDA-MB-468 and MCF-7 cells, the top 10% of 
cells with the highest fluorescence were collected as the ALDH1+ 
cell population, while the bottom 10% of cells were collected as the 
ALDH1– cell population. For primary breast cancer cells, the top 3% 
of cells with the highest fluorescence were collected as the ALDH1+ 
cell population, while the bottom 10% of cells were collected as the 
ALDH1– cell population.
Mammosphere-forming assay. Cells were digested by trypsin and 
disrupted into single-cell suspensions. Then, cells were cultured in 
MammoCult medium (STEMCELL Technologies), including 4 μg/ml 
heparin (STEMCELL Technologies), 0.48 μg/ml hydrocortisone 
(STEMCELL Technologies), 100 units/ml penicillin, and 100 μg/ml 
streptomycin in Corning Ultra-Low Attachment 6-well plates at 
a density of 2 × 104 cells/2 ml for 7 to 10 days every generation. 
Figure 8. Lys-353 acetylation of ALDH1A1 inhibits breast tumorigenesis and tumor growth. (A) ALDH1A1K353Q was 
compromised to support breast cancer cell proliferation. MDA-MB-468 cells with stably knocked down ALDH1A1 and 
reintroduced ALDH1A1WT or ALDH1A1K353Q were seeded into each well. Cell numbers were counted every 48 hours (error 
bars represent the mean ± SD of triplicate experiments). (B) MDA-MB-468 cells expressing ALDH1A1K353Q showed 
reduced TIC frequencies. Xenografting into mammary fat pads was performed using different concentrations  
(5 × 105, 5 × 104, 5 × 103, 1 × 103, 200, and 40 cells per mouse) of endogenous ALDH1A1-knockdown MDA-MB-468 cells 
that expressed either ALDH1A1WT or ALDH1A1K353Q. After 3 weeks, their tumorigenesis was determined, and TIC frequen-
cies were calculated with L-Calc software. (C) ALDH1A1K353Q was defective in supporting tumor growth in vivo. Tumor 
sizes from the mouse injected with 5 × 105, 5 × 104, and 5 × 103 cells were monitored every week after tumor formation. 
Tumor growth derived from the mice injected with 5 × 103 cells is shown. (B and C) P values were calculated by Stu-
dent’s t test. (D) Schematic illustration of NOTCH-mediated ALDH1A1 K353 deacetylation in the promotion of breast 
CSCs. High ALDH1A1 activity is required to maintain breast CSCs. K353 acetylation reduces ALDH1A1 enzyme activity, 
thereby inhibiting self-renewal of breast CSCs. NOTCH signaling is elevated in breast CSCs, and NOTCH induces SIRT2 
to deacetylate and activate ALDH1A1 to maintain breast CSCs. NICD, NOTCH intracellular domain; Ac, acetylation.
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template for quantitative PCR (SYBR Premix Ex Taq, Tli RNase H 
Plus; Clontech, Takara Bio Company) with several pairs of primers 
targeting the SIRT2 promoter regions (primer information refers to 
Supplemental Figure 6E).
Cell proliferation. MDA-MB-468 stable cell lines with ALDH1A1 
knockdown and reexpressed shRNA-resistant WT or K353Q-mutant 
ALDH1A1 were prepared. Cells (1 × 105) were seeded in triplicate 
on plates, and cell numbers were counted every 2 days over an 
8-day period.
Mouse breast cancer model. Female 5- to 6-week-old NOD/
SCID mice were used to assess the in vivo stem cell properties and 
tumor growth of breast cancer as described previously (6, 40). 
MDA-MB-468 cells, which knocked down ALDH1A1 and expressed 
ALDH1A1WT or ALDH1A1K353Q , were injected into the mammary 
fat pads of female mice. Cell concentrations included 5 × 105, 
5 × 104, 5 × 103, 1 × 103, 200, and 40 cells/100 μl/mouse containing 
50 μl Matrigel (BD Biosciences), and reexpressing ALDH1A1WT or 
ALDH1A1K353Q cells were paired and injected into each side of the 
NOD/SCID mice. Then, the mice were observed for tumorigenesis 
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